<DOC>
	<DOCNO>NCT02141438</DOCNO>
	<brief_summary>Observational study routine clinical practice set evaluate short long term safety profile Radium-223 metastatic castration resistant prostate cancer patient evaluate risk develop second primary cancer .</brief_summary>
	<brief_title>Observational Study Evaluation Long-term Safety Radium-223 Used Treatment Metastatic Castration Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Treatment decision Radium223 need make independent patient enrollment study Histologically cytologically confirm castration resistant adenocarcinoma prostate bone metastasis Signed informed consent Previously treat Radium223 reason Currently treat clinical trial include Radium223 study Planned systemic concomitant use radiopharmaceutical treatment prostate cancer use</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Radium-223</keyword>
	<keyword>Metastatic castration-resistant prostate cancer</keyword>
	<keyword>CRPC</keyword>
	<keyword>Phase IV</keyword>
	<keyword>Safety study</keyword>
</DOC>